The GLOW phase III study enrolled 507 patients with HER2-negative, locally advanced or metastatic GC/GEJC, randomized to receive either zolbetuximab plus CAPOX, or CAPOX plus placebo. The gene discussed is ERBB2; the disease is gastric cancer.